Trends in Molecular Medicine:脂肪组织中这种蛋白会促进乳腺癌发展!

2020-04-15 竹子 转化医学网

导言:众所周知,较高的体内脂肪会增加患乳腺癌以及其他癌症的风险。詹姆斯·格雷厄姆·布朗癌症中心的研究人员发现,有13种癌症都与肥胖有关,而不仅仅是乳腺癌。

导言:众所周知,较高的体内脂肪会增加患乳腺癌以及其他癌症的风险。詹姆斯·格雷厄姆·布朗癌症中心的研究人员发现,有13种癌症都与肥胖有关,而不仅仅是乳腺癌。那么,脂肪组织中是否存在着某种物质在癌症(尤其是乳腺癌)与脂肪细胞之间起关键作用呢?

近日,詹姆斯·格雷厄姆·布朗癌症中心副教授,路易斯维尔大学(UofL)微生物、免疫学和健康学系李冰(Bing Li)博士发表了一篇文章。根据他正在进行的研究,提出了一种独特的理论,即脂肪组织中表达的脂肪酸结合蛋白(FABP4)可以促进乳腺癌肿瘤的生长。李在上周在线出版的细胞出版社杂志《分子医学趋势》的邀请论坛上分享了此论点。

早先就有研究探讨了膜突蛋白促进乳腺癌细胞侵袭转移机制,后又有研究从膜周边蛋白FABP4切入研究,表明其可以促进乳腺癌细胞的侵袭转移,机制可能是促进乳腺癌细胞IL-33的分泌有关。FABP4是脂肪酸结合蛋白家族的一员,能够结合多种疏水性化合物,例如长链脂肪酸、多种环氧化酶和脂肪氧化产物,同时参与其代谢和信号转导过程,并在糖尿病、肥胖和脂代谢紊乱等疾病的形成中发挥着关键作用。

在过去的五年中,李一直进行着由美国国家癌症研究所资助的研究,这使他认识到脂肪组织中表达的蛋白质的活性与乳腺癌发展的增加之间存在联系。他发现,脂肪酸结合蛋白家族,尤其是FABP4,在肥胖与癌症(尤其是乳腺癌)的关联中起着至关重要的作用。FABP4负责潜在的分子机制,促进跟肥胖相关的乳腺癌的发展。

人体中的脂肪组织在脂肪细胞内产生FABP4,在脂肪细胞中加工并分布不溶于水的长链脂肪酸。在正常情况下,一定量的FABP4进入血液。但是,随着脂肪组织积累量增加,更多的FABP4分泌进入循环系统。一个人变胖时,这种蛋白质会更多地分泌到循环系统中。通常这些分子在细胞内,但是当人们变胖时,这些分子在细胞外。

这项研究提供了FABP4刺激乳腺癌肿瘤生长的两种方式。首先,在细胞内,FABP4在某些与肿瘤相关的巨噬细胞中增加,这些巨噬细胞在肿瘤中积累以促进肿瘤生长。研究还显示,当FABP4被抑制时,即使脂肪组织残留,在动物模型中肿瘤的生长也会减少。其次,当肥胖中脂肪细胞外循环的FABP4水平升高时,该蛋白通过与乳腺癌细胞直接相互作用而促进乳腺癌的发展。在动物研究中,FAFA4受控制的肥胖动物的乳腺肿瘤发育和生长减少。

血液中的FABP4似乎以多种机制起作用,以促进肿瘤成分与脂肪细胞之间的相互作用,从而促进癌症的发展。

此外,研究小组最近在《癌症研究》上发表了研究结果,表明不同类型的高脂饮食对肿瘤的发展有不同的影响。高脂饮食的可可脂或鱼油都会导致肥胖。但是,可可脂饮食会增加乳腺肿瘤的生长,而鱼油饮食则不会。这项研究不仅证实了FABP4在与肥胖相关的癌症中的关键作用,而且揭示了一个道理:并非所有的肥胖都会促进肿瘤的发展。

研究人员相信,理解FABP4在巨噬细胞内和循环中如何运作,可以为预防某些乳腺癌的发展提供机会。它还可能促进研究人员开发以药物或特异性抗体靶向FABP4的治疗方法。这可能是一个非常有效的策略,还能治疗其他与肥胖相关的癌症。

原始出处:

Jun Zeng, Edward R. Sauter, Bing Li. FABP4: A New Player in Obesity-Associated Breast Cancer. Trends in Molecular Medicine April 07, 2020

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1773850, encodeId=bc1f1e738509f, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 02 19:09:13 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905722, encodeId=cb1e1905e22ae, content=<a href='/topic/show?id=2ebd1e7981a' target=_blank style='color:#2F92EE;'>#trend#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17798, encryptionId=2ebd1e7981a, topicName=trend)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Thu Feb 25 19:09:13 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785294, encodeId=4aee1e85294cd, content=<a href='/topic/show?id=51906e79a6' target=_blank style='color:#2F92EE;'>#ENDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6779, encryptionId=51906e79a6, topicName=ENDS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sun Feb 28 18:09:13 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859044, encodeId=a546185904440, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 19 21:09:13 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345807, encodeId=426a134580efb, content=<a href='/topic/show?id=f8c5843e3c5' target=_blank style='color:#2F92EE;'>#脂肪组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84373, encryptionId=f8c5843e3c5, topicName=脂肪组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577716, encodeId=020515e7716b0, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610434, encodeId=86d91610434bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=)]
    2021-03-02 kalseyzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1773850, encodeId=bc1f1e738509f, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 02 19:09:13 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905722, encodeId=cb1e1905e22ae, content=<a href='/topic/show?id=2ebd1e7981a' target=_blank style='color:#2F92EE;'>#trend#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17798, encryptionId=2ebd1e7981a, topicName=trend)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Thu Feb 25 19:09:13 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785294, encodeId=4aee1e85294cd, content=<a href='/topic/show?id=51906e79a6' target=_blank style='color:#2F92EE;'>#ENDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6779, encryptionId=51906e79a6, topicName=ENDS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sun Feb 28 18:09:13 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859044, encodeId=a546185904440, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 19 21:09:13 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345807, encodeId=426a134580efb, content=<a href='/topic/show?id=f8c5843e3c5' target=_blank style='color:#2F92EE;'>#脂肪组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84373, encryptionId=f8c5843e3c5, topicName=脂肪组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577716, encodeId=020515e7716b0, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610434, encodeId=86d91610434bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=)]
    2021-02-25 freve
  3. [GetPortalCommentsPageByObjectIdResponse(id=1773850, encodeId=bc1f1e738509f, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 02 19:09:13 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905722, encodeId=cb1e1905e22ae, content=<a href='/topic/show?id=2ebd1e7981a' target=_blank style='color:#2F92EE;'>#trend#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17798, encryptionId=2ebd1e7981a, topicName=trend)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Thu Feb 25 19:09:13 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785294, encodeId=4aee1e85294cd, content=<a href='/topic/show?id=51906e79a6' target=_blank style='color:#2F92EE;'>#ENDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6779, encryptionId=51906e79a6, topicName=ENDS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sun Feb 28 18:09:13 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859044, encodeId=a546185904440, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 19 21:09:13 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345807, encodeId=426a134580efb, content=<a href='/topic/show?id=f8c5843e3c5' target=_blank style='color:#2F92EE;'>#脂肪组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84373, encryptionId=f8c5843e3c5, topicName=脂肪组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577716, encodeId=020515e7716b0, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610434, encodeId=86d91610434bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1773850, encodeId=bc1f1e738509f, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 02 19:09:13 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905722, encodeId=cb1e1905e22ae, content=<a href='/topic/show?id=2ebd1e7981a' target=_blank style='color:#2F92EE;'>#trend#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17798, encryptionId=2ebd1e7981a, topicName=trend)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Thu Feb 25 19:09:13 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785294, encodeId=4aee1e85294cd, content=<a href='/topic/show?id=51906e79a6' target=_blank style='color:#2F92EE;'>#ENDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6779, encryptionId=51906e79a6, topicName=ENDS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sun Feb 28 18:09:13 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859044, encodeId=a546185904440, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 19 21:09:13 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345807, encodeId=426a134580efb, content=<a href='/topic/show?id=f8c5843e3c5' target=_blank style='color:#2F92EE;'>#脂肪组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84373, encryptionId=f8c5843e3c5, topicName=脂肪组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577716, encodeId=020515e7716b0, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610434, encodeId=86d91610434bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=)]
    2020-04-19 jeanqiuqiu
  5. [GetPortalCommentsPageByObjectIdResponse(id=1773850, encodeId=bc1f1e738509f, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 02 19:09:13 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905722, encodeId=cb1e1905e22ae, content=<a href='/topic/show?id=2ebd1e7981a' target=_blank style='color:#2F92EE;'>#trend#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17798, encryptionId=2ebd1e7981a, topicName=trend)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Thu Feb 25 19:09:13 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785294, encodeId=4aee1e85294cd, content=<a href='/topic/show?id=51906e79a6' target=_blank style='color:#2F92EE;'>#ENDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6779, encryptionId=51906e79a6, topicName=ENDS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sun Feb 28 18:09:13 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859044, encodeId=a546185904440, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 19 21:09:13 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345807, encodeId=426a134580efb, content=<a href='/topic/show?id=f8c5843e3c5' target=_blank style='color:#2F92EE;'>#脂肪组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84373, encryptionId=f8c5843e3c5, topicName=脂肪组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577716, encodeId=020515e7716b0, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610434, encodeId=86d91610434bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1773850, encodeId=bc1f1e738509f, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 02 19:09:13 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905722, encodeId=cb1e1905e22ae, content=<a href='/topic/show?id=2ebd1e7981a' target=_blank style='color:#2F92EE;'>#trend#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17798, encryptionId=2ebd1e7981a, topicName=trend)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Thu Feb 25 19:09:13 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785294, encodeId=4aee1e85294cd, content=<a href='/topic/show?id=51906e79a6' target=_blank style='color:#2F92EE;'>#ENDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6779, encryptionId=51906e79a6, topicName=ENDS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sun Feb 28 18:09:13 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859044, encodeId=a546185904440, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 19 21:09:13 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345807, encodeId=426a134580efb, content=<a href='/topic/show?id=f8c5843e3c5' target=_blank style='color:#2F92EE;'>#脂肪组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84373, encryptionId=f8c5843e3c5, topicName=脂肪组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577716, encodeId=020515e7716b0, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610434, encodeId=86d91610434bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1773850, encodeId=bc1f1e738509f, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Tue Mar 02 19:09:13 CST 2021, time=2021-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905722, encodeId=cb1e1905e22ae, content=<a href='/topic/show?id=2ebd1e7981a' target=_blank style='color:#2F92EE;'>#trend#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17798, encryptionId=2ebd1e7981a, topicName=trend)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Thu Feb 25 19:09:13 CST 2021, time=2021-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785294, encodeId=4aee1e85294cd, content=<a href='/topic/show?id=51906e79a6' target=_blank style='color:#2F92EE;'>#ENDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6779, encryptionId=51906e79a6, topicName=ENDS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sun Feb 28 18:09:13 CST 2021, time=2021-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1859044, encodeId=a546185904440, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sun Apr 19 21:09:13 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1345807, encodeId=426a134580efb, content=<a href='/topic/show?id=f8c5843e3c5' target=_blank style='color:#2F92EE;'>#脂肪组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84373, encryptionId=f8c5843e3c5, topicName=脂肪组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66962500501, createdName=yige2004, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577716, encodeId=020515e7716b0, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610434, encodeId=86d91610434bb, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Apr 17 05:09:13 CST 2020, time=2020-04-17, status=1, ipAttribution=)]
    2020-04-17 智慧医人

相关资讯

盘点:2020年度J Clin Oncol杂志回顾汇总(三)

J Clin Oncol:2020年ASCO临床肿瘤学年度进展报告

王海波教授专访:non-pCR乳腺癌治疗新添利器

T-DM1作为乳腺癌治疗领域首个ADC类药物,现已在我国获批上市,用于HER2阳性早期乳腺癌新辅助治疗后未达病理学完全缓解患者术后的强化辅助治疗。那么,该药的化学结构和作用机制是怎样的?在临床使用中具

规范不失有效——俞乔教授谈疫情期间乳腺癌诊疗活动开展

一场突如其来的新型冠状病毒肺炎疫情,严重打乱了国人的生活节奏,对于恶性肿瘤患者更是一个沉重打击。一方面,肿瘤患者免疫力相对低下,成为新冠肺炎的易感者。另一方面,在感染新冠肺炎后,肿瘤患者死亡率明显升高

JAMA Oncol:延迟靶向术中放疗与全乳放疗对乳腺癌局部复发和存活的影响(TARGIT-A长期结果)

传统的乳癌辅助放射治疗,每天进行为期数周的放射治疗,既繁重又昂贵。有些患者可能不得不选择切除乳房,有些人可能会放弃放疗。研究确定延迟的二次手术靶向术中放疗(TARGIT-IORT)是否比传统外照射放疗

Radiology:小心漏诊乳腺癌患者腋窝前哨淋巴结!

越来越多的乳腺癌患者在新辅助化疗(NAC)后进行了前哨淋巴结活检(SLNB)。

佟仲生教授专访:因势利导,ADC药物开启乳腺癌治疗新时代

2020年1月21日,T-DM1(恩美曲妥珠单抗)在中国获批,其作为我国首个获批的ADC类药物,相比传统治疗药物具备何种优势?T-DM1的应用场景又有哪些?该药上市后,乳腺癌治疗又该何去何从?

拓展阅读

大至8.9厘米的肿瘤不能手术怎么办?冷冻治疗仅需半小时,患者当天可回家

尽管乳腺癌可以比较早期的发现,但是仍然有很多的患者发现罹患乳腺癌的时候面临治疗困境,假设肿瘤可以通过手术治疗,但是有很多人因为各种原因不能进行手术,比如肿瘤比较大的情况,手术就不是很理想的治疗方式。

徐兵河院士:乳腺癌临床研究的进展与未来

在2024南北汇暨第六届中华乳腺肿瘤论坛上,中国医学科学院肿瘤医院徐兵河院士分享了学术报告——《乳腺癌临床研究的进展与未来》,重点分享了其所在团队取得的研究成果。

《新英格兰医学》最新报道,瑞博西尼可降低25%的乳腺癌复发!

为了降低乳腺癌的术后复发风险,研究者开始考虑将一款细胞周期蛋白依赖激酶4/6的抑制剂加入,这类药物主要是用来调控细胞增殖,比较为大家所知的就是瑞博西尼。

论文解读|Yang Liu/Pan Zheng教授团队揭示创新型RNA递送平台在癌症治疗中的前景

这项研究展示了一个新型的递送平台,它使用镁来形成纳米颗粒,实现了有针对性、高效和安全的RNA递送,对乳腺癌的潜在治疗效益也得到了证明。

Lancet Oncol | coopERA Breast Cancer研究:新辅助哌柏西利加giredestrant或阿那曲唑治疗雌激素受体阳性、HER2阴性的乳腺癌

该研究旨在比较哌柏西利加giredestrant或阿那曲唑治疗雌激素受体阳性、HER2阴性的乳腺癌的疗效和安全性,giredestrant较阿那曲唑能更有效地抑制肿瘤增殖且安全可控。

European Radiology:MR在预测乳腺癌新辅助化疗病理完全缓解中的附加价值

MRI是NAC治疗前分期和肿瘤反应监测的首选方法,并可以使用形态学和功能学参数 (如弥散加权成像)来提高NAC治疗后肿瘤反应的预测。